Drug Subsidies & Schemes 

Tags:

The Ministry of Health (MOH) provides subsidies for drugs at our public hospitals, specialist outpatient clinics (SOCs) and polyclinics to ensure that patients have access to effective medications for common medical conditions in Singapore.

Subsidies and financial assistance are given for drugs approved under the Standard Drug List (SDL) and Medication Assistance Fund (MAF). Drugs approved under the SDL and MAF must be registered with the Health Sciences Authority (HSA) and assessed to be clinically- and cost-effective. MAF drugs are generally newer and more expensive, and therefore MAF applies only when these drugs are used for suitable clinical indications so that MAF drugs are appropriately used. In exceptional cases, MAF can also support HSA-registered drugs that are not on the SDL or MAF list, on a case-by-case basis.

The drugs listed on this page are reviewed and updated on a regular basis by MOH to take into account changes in clinical practice, advances in medical science, and the evolving needs of patients. Should you require further clarification about your medications, please consult your physician or pharmacist for assistance.

Frequently Asked Questions

Have more questions? Check out our Frequently Asked Questions on the Medication Assistance Fund.

List of Drugs* (as of 1 March 2018)

* The drug availability at each healthcare institution varies, depending on the clinical conditions commonly managed by the institution and the drugs usually prescribed by the doctors.

Active Ingredient(s) Dosage Form Strength Subsidy Class Clinical Indication (where applicable)
Absolute AlcoholInjection100%SDL--
AcetazolamideTablet250mgSDL--
Acetic acidEar Drops2%SDL--
AcetylcysteineInjection2g/ 10mLSDL--
AcetylcysteineInjection5g/ 25mLSDL--
AciclovirConcentrate for Infusion250mg/ 10mLSDL--
AciclovirInfusion250mgSDL--
AciclovirEye Ointment3%SDL--
AcitretinCapsule10mgSDL--
AcitretinCapsule25mgSDL--
AdalimumabPrefilled Pen40mg/ 0.8mLMAF1) Treatment of adult patients with rheumatoid arthritis
2) Treatment of adult patients with psoriatic arthritis
3) Treatment of adult patients with ankylosing spondylitis
4) Treatment of adult patients with Crohn's disease
5) Treatment of adult patients with ulcerative colitis
6) Treatment of adult patients with chronic plaque psoriasis
7) Treatment of children (age 6 years or older) with Crohn's disease
8) Treatment of juvenile idiopathic arthritis
AdalimumabPrefilled Syringe40mg/ 0.8mLMAF1) Treatment of adult patients with rheumatoid arthritis
2) Treatment of adult patients with psoriatic arthritis
3) Treatment of adult patients with ankylosing spondylitis
4) Treatment of adult patients with Crohn's disease
5) Treatment of adult patients with ulcerative colitis
6) Treatment of adult patients with chronic plaque psoriasis
7) Treatment of children (age 6 years or older) with Crohn's disease
8) Treatment of juvenile idiopathic arthritis
Adefovir DipivoxilTablet10mgSDL--
AdrenalineInjection1:1,000 (1mg/ mL)SDL--
AdrenalineInjection1:10,000 (1mg/ 10mL)SDL--
AlbendazoleOral Suspension400mg/ 10mlSDL--
AlbendazoleTablet400mgSDL--
AlcuroniumInjection10mg/ 2mLSDL--
Alendronic AcidTablet10mgSDL--
Alendronic AcidTablet70mgSDL--
Alendronic Acid & ColecalciferolTabletAlendronic Acid 70mg + Colecalciferol 2,800 international unitMAF1) For patients with osteoporosis (T-score <= -2.5)
2) For patients with osteopenia (T-score <= -1.5) and a history of non-trauma induced fracture
Alendronic Acid & ColecalciferolTabletAlendronic Acid 70mg + Colecalciferol 5,600 international unitMAF1) For patients with osteoporosis (T-score <= -2.5)
2) For patients with osteopenia (T-score <= -1.5) and a history of non-trauma induced fracture
AlfacalcidolCapsule0.25mcgSDL--
AlfacalcidolCapsule1mcgSDL--
AlfacalcidolOral Drops2mcg/ mLSDL--
AlfacalcidolTablet0.25mcgSDL--
AlfacalcidolTablet1mcgSDL--
Alginic Acid, Sodium Bicarbonate, Aluminium Hydroxide & Magnesium TrisilicateChewable TabletAlginic Acid 500mg + Sodium Bicarbonate 170mg + Aluminium Hydroxide (dried gel) 100mg + Magnesium Trisilicate 25mgSDL
AllopurinolTablet100mgSDL--
AllopurinolTablet300mgSDL--
AlteplaseInfusion50mg/ 50mLSDL--
Aluminium HydroxideTablet600mgSDL--
Aluminium Hydroxide, Magnesium Trisilicate & SimeticoneChewable TabletAluminium Hydroxide 250mg + Magnesium Trisilicate 250mg + Simeticone 30mgSDL--
Aluminium OxideOral Suspension4%SDL--
AmikacinInjection500mg/ 2mLSDL--
Amiloride & HydrochlorothiazideTabletHydrochlorothiazide 50 mg + Amiloride Hydrochloride 5 mgSDL--
Amino AcidsInfusion5%, 10%SDL--
AminophyllineInjection250mg/ 10mLSDL--
Amiodarone HydrochlorideInjection50mg/ mLSDL--
Amiodarone HydrochlorideTablet200mgSDL--
AmitriptylineTablet10mgSDL--
AmitriptylineTablet25mgSDL--
AmlodipineTablet5mgSDL--
AmlodipineTablet10mgSDL--
AmoxicillinCapsule250mgSDL--
AmoxicillinOral Suspension125mg/ 5mLSDL--
Amoxicillin & Clavulanic AcidInjectionAmoxicillin 500mg + Clavulanic Acid 100mgSDL--
Amoxicillin & Clavulanic AcidInjectionAmoxicllin 1g + Clavulanic Acid 200mgSDL--
Amoxicillin & Clavulanic AcidOral SuspensionAmoxicillin 200mg/ 5mL + Clavulanic Acid 28.5mg/ 5mLSDL--
Amoxicillin & Clavulanic AcidTabletAmoxicillin 500mg + Clavulanic Acid 125mg SDL--
Amoxicillin & Clavulanic AcidOral SuspensionAmoxicillin 600mg/ 5mL + Clavulanic Acid 42.9mg/ 5mLSDL--
Amoxicillin & Clavulanic AcidTabletAmoxicillin 875mg + Clavulanic Acid 125mg SDL--
Amphotericin BInjection50mgSDL--
Amphotericin BEye Drops1mg/ mLSDL--
AmpicillinInjection0.5gSDL--
AnastrozoleTablet1mgMAFTreatment of hormone receptor positive, postmenopausal women with early and advanced breast cancer
Antazoline Hydrochloride & Tetryzoline HydrochlorideEye DropsAntazoline Hydrochloride 0.5 mg/ mL + Tetryzoline Hydrochloride 0.4 mg/ mLSDL--
Anti-Rabies ImmunoglubulinInjection300 unit/ 2mLSDL--
AprepitantCapsule80mgMAFPrevention of chemotherapy induced nausea and vomiting in patients receiving high dose cisplatin
AprepitantCapsule125mgMAFPrevention of chemotherapy induced nausea and vomiting in patients receiving high dose cisplatin
AprepitantCapsule80 mg Capsule (&) 125 mg Capsule (3 capsules)MAFPrevention of chemotherapy induced nausea and vomiting in patients receiving high dose cisplatin
Aqueous CreamCreamEmulsifying Ointment 30% with either Chlorocresol 0.1% or Phenoxyethanol 0.1%SDL--
Ascorbic AcidInjection1g/ 20mLSDL--
Ascorbic AcidTablet100mgSDL--
AspirinTablet100mgSDL--
AspirinTablet300mgSDL--
AtenololTablet50mgSDL--
AtenololTablet100mgSDL--
AtorvastatinTablet10mgSDL--
AtorvastatinTablet20mgSDL--
AtorvastatinTablet40mgSDL--
AtorvastatinTablet80mgSDL--
AtracuriumInjection25mg/ 2.5mLSDL--
AtracuriumInjection50mg/ 5mLSDL--
Atropine SulfateInjection0.6mg/ mLSDL--
Atropine SulfateInjection6mg/ mLSDL--
Atropine SulfateEye Drops0.50%SDL--
Atropine SulfateEye Drops1%SDL--
AzathioprineTablet50mgSDL--
AzithromycinExtended-Release Oral Suspension2gSDL--
AzithromycinInjection500mgSDL--
AzithromycinOral Suspension200mg/ 5mLSDL--
AzithromycinTablet250mgSDL--
Active Ingredient(s) Dosage Form Strength Subsidy Class Clinical Indication (where applicable)
Bacillus Calmette-GuerinSolution for Intravesical Use27mgSDL--
Bacillus Calmette-GuerinSolution for Intravesical Use81mgSDL--
Bacillus Calmette-Guerin VaccineInjection0.75 mg/ mLSDL--
Bacitracin, Polymyxin & NeomycinPowderBacitracin Zinc 400u/ g + Polymyxin B Sulfate 5,000u/ g + Neomycin Sulfate 3,400u/ gSDL--
BeclomethasoneInhaler250mcg/ doseSDL--
Beclomethasone DipropionateInhaler50 mcg/ doseSDL--
BentoniteSuspension7%SDL--
Benzalkonium Chloride & CetrimideCreamBenzalkonium Chloride 0.01% + Cetrimide 0.2%SDL--
Benzathine BenzylpenicillinInjection2.4 million international unitSDL--
BenzatropineInjection2mg/ 2mLSDL--
Benzatropine MesilateTablet2mgSDL--
Benzhexol HydrochlorideTablet2mgSDL--
Benzoyl PeroxideGel2.50%SDL--
Benzoyl PeroxideGel5%SDL--
Benzoyl PeroxideGel10%SDL--
Benzyl BenzoateTopical Emulsion25%SDL--
Benzylpenicillin SodiumInjection5 million international unitSDL--
Benzylpenicillin SodiumEye Drops (preservative-free)2,500 international unit/ mLSDL--
Betahistine MesilateTablet6mgSDL--
Betamethasone (as Valerate)Cream0.025%SDL--
Betamethasone (as Valerate)Cream0.05%SDL--
Betamethasone (as Valerate)Cream0.10%SDL--
Betamethasone (as Valerate)Ointment0.025%SDL--
Betamethasone (as Valerate)Ointment0.05%SDL--
Betamethasone (as Valerate)Ointment0.10%SDL--
Betamethasone (as Valerate)Scalp Lotion0.10%SDL--
Betamethasone (as Valerate) & ClioquinolCreamBetamethasone 0.025% + Clioquinol 3%SDL--
Betamethasone (as Valerate) & ClioquinolCream Betamethasone 0.05% + Clioquinol 3%SDL--
Betamethasone (as Valerate) & ClioquinolCreamBetamethasone 0.1% + Clioquinol 3%SDL--
Betamethasone Sodium PhosphateEye/ Ear Drops0.10%SDL--
Betamethasone Sodium PhosphateEye/ Ear Drops0.10%SDL--
BetaxololEye Drops0.25%SDL--
Bethanechol ChlorideTablet10mgSDL--
BevacizumabIntravitreal Injection25mg/mLMAF1) Treatment of adults with visual impairment due to neovascular (wet) age-related macular degeneration
2) Treatment of adults with visual impairment due to macular oedema secondary to central or branch retinal vein occlusion
3) Treatment of adults with visual impairment due to diabetic macular oedema
BisacodylEnteric-Coated Tablet5mgSDL--
BisacodylRectal Suppository10mgSDL--
Bismuth SubcitrateTablet300mgSDL--
Bismuth SubgallateRectal SuppositoryBismuth Subgallate 200mg + Zinc Oxide 120mgSDL--
Bismuth SubnitratePaste10%SDL--
Bisoprolol FumarateTablet2.5mgSDL--
Bisoprolol FumarateTablet5mg SDL--
BleomycinInjection15mgSDL--
Boric Acid, Resorcinol & PhenolPaintBoric Acid 0.8% + Resorcinol 8% + Phenol 4%SDL--
BortezomibInjection3.5mgMAFFor Primary induction in newly diagnosed patients with symptomatic multiple myeloma
Botulinum toxin type A complex (Botox)Injection50 unitMAFFor adults with focal spasticity of the upper limbs due to stroke, who have Modified Ashworth Scale of 2 or more at the target muscle intended for botulinum toxin A treatment, and do not have the affected joint permanently fixed in position due to fibrotic shortening of the target muscle and are concurrently receiving physiotherapy
Brimonidine TartrateEye Drops0.15%SDL--
BromocriptineTablet2.5mgSDL--
BromocriptineTablet2.5mgSDL--
Buclizine HydrochlorideTablet25mgSDL--
BudesonideInhaler100mcg/ doseMAFFor patients with asthma
BudesonideInhaler200mcg/ doseMAFFor patients with asthma
BudesonidePowder Inhaler200mcg/ doseSDL--
BudesonidePowder Inhaler100mcg/ doseSDL--
Bupivacaine Hydrochloride (hyperbaric)Injection0.5% (in dextrose 8%)SDL--
Bupivacaine Hydrochloride (isobaric)Injection0.50%SDL--
BuprenorphineSublingual Tablet0.2mgSDL--
BusulfanTablet2mgSDL--
BusulfanInjection60mgSDL--
Active Ingredient(s) Dosage Form Strength Subsidy Class Clinical Indication (where applicable)
CabergolineTablet0.5mgMAFAs a 2nd line agent for the management of hyperprolactinaemia in patients who have failed to respond or who are unable to tolerate Bromocriptine
CalamineLotionCalamine 15%SDL--
Calamine & MentholLotionCalamine 15% + Menthol 0.4%SDL--
CalcipotriolCream50mcg/ gSDL--
CalcipotriolOintment50mcg/ gSDL--
CalcipotriolScalp Solution50mcg/ mLSDL--
Calcipotriol & BetamethasoneGelCalcipotriol 50mcg/ g + Betamethasone (as Diproprionate) 0.5mg/ gSDL--
Calcipotriol & BetamethasoneOintmentCalcipotriol 50mcg/ g + Betamethasone (as Diproprionate) 0.5mg/ gSDL--
CalcitriolCapsule0.25mcgSDL--
CalcitriolCapsule0.5mcgSDL--
CalciumSyrup20 to 23mg Ca2+/ mLSDL--
Calcium AcetateTablet667mgSDL--
Calcium CarbonateChewable Tablet1.25gSDL--
Calcium CarbonateTablet625mgSDL--
Calcium Carbonate & ColecalciferolTabletCalcium Carbonate 450mg + Colecalciferol 5mcgSDL--
Calcium Chloride DihydrateInjection10%SDL--
Calcium Chloride DihydrateInjection10%SDL--
Calcium GluconateInjection10%SDL--
Calf Blood Extract (deproteinised)Eye Gel8.3mg/ gSDL--
Candesartan CilexetilTablet4mgMAFTreatment of patients with heart failure who cannot tolerate angiotensin converting enzyme inhibitors
Candesartan CilexetilTablet8mgMAFTreatment of patients with heart failure who cannot tolerate angiotensin converting enzyme inhibitors
Candesartan CilexetilTablet16mgMAFTreatment of patients with heart failure who cannot tolerate angiotensin converting enzyme inhibitors
CapecitabineTablet150 mgSDL--
CapecitabineTablet500 mgSDL--
CaptoprilTablet12.5mgSDL--
CaptoprilTablet25mgSDL--
CarbamazepineControlled-Release Tablet200mgSDL--
CarbamazepineControlled-Release Tablet400mgSDL--
CarbamazepineSyrup100mg/ 5mLSDL--
CarbamazepineTablet200mgSDL--
CarbimazoleTablet5mgSDL--
CarboplatinInjection150mg/ mLSDL--
CarboplatinInjection10mg/ mLSDL--
CarmustineInjection100mgSDL--
CarvedilolTablet6.25mgSDL--
CarvedilolTablet12.5mgSDL--
CarvedilolTablet25mgSDL--
CefalexinCapsule250mgSDL--
CefalexinOral Suspension125mg/ 5mLSDL--
CefazolinInjection1gSDL--
CeftazidimeInjection1gSDL--
CeftriaxoneInjection250mgSDL--
CeftriaxoneInjection1gSDL--
CeftriaxoneInjection2gSDL--
CetirizineSolution1mg/ mLSDL--
CetrimideTopical Solution 1%SDL--
CetrimideShampoo5%SDL--
Charcoal (activated)Oral Suspension200mg/ mL (in sorbitol 70%)SDL--
Charcoal (activated)Tablet250mgSDL--
Charcoal (activated)Granules 50gSDL--
Chloral HydrateOral Solution200mg/ 5mLSDL--
Chloral HydrateOral Solution500mg/ 5mLSDL--
ChlorambucilTablet2mgSDL--
ChloramphenicolCapsule250mgSDL--
ChloramphenicolInjection1gSDL--
ChloramphenicolEye Drops0.50%SDL--
ChloramphenicolEye Ointment1%SDL--
Chlorhexidine & Sodium Nitrite in SpiritTopical Solution Chlorhexidine 0.02% + Sodium nitrite 0.1% in Spirit 70%SDL--
Chlorhexidine AcetateIrrigation Solution0.02%SDL--
Chlorhexidine GluconateCream1%SDL--
Chlorhexidine SaltMouth Wash0.20%SDL--
Chlorhexidine SaltTopical Solution 0.05%SDL--
Chlorhexidine SaltTopical Solution 0.10%SDL--
Chlorhexidine SaltTopical Solution4%SDL--
Chlorhexidine SaltMouth Wash0.20%SDL--
Chlorhexidine Salt & AlcoholTopical Solution Chlorhexidine Salt 0.1% + Alcohol 70%SDL--
Chlorhexidine Salt & AlcoholTopical Solution Chlorhexidine Salt 0.5% + Alcohol 70%SDL--
Chlorhexidine Salt & CetrimideTopical Solution Chlorhexidine Salt 0.015% + Cetrimide 0.15%SDL--
Chloroquine PhosphateTablet150mgSDL--
ChlorpheniramineSyrup4mg/ 5mLSDL--
ChlorpheniramineTablet4mgSDL--
ChlorpromazineInjection50mg/ 2mLSDL--
ChlorpromazineTablet25mgSDL--
ChlorpromazineTablet100mgSDL--
ChlorpropamideTablet250mgSDL--
ChlortetracyclineEye Ointment1%SDL--
Choline SalicylateOral Gel9%SDL--
CiclosporinCapsule10mgSDL1) Prevention of organ rejection in bone marrow and solid organ transplant
2) Treatment of primary nephrotic syndrome
3) Treatment of psoriasis
CiclosporinCapsule25mgSDL1) Prevention of organ rejection in bone marrow and solid organ transplant
2) Treatment of primary nephrotic syndrome
3) Treatment of psoriasis
CiclosporinCapsule100mg SDL1) Prevention of organ rejection in bone marrow and solid organ transplant
2) Treatment of primary nephrotic syndrome
3) Treatment of psoriasis
CiclosporinOral Solution100mg/ mLSDL1) Prevention of organ rejection in bone marrow and solid organ transplant
2) Treatment of primary nephrotic syndrome
3) Treatment of psoriasis
CimetidineInjection200mg/ 2mLSDL--
CimetidineInjection150mg/ mLSDL--
CimetidineTablet200mgSDL--
CiprofloxacinInfusion2mg/ mLSDL--
CiprofloxacinTablet250mgSDL--
CiprofloxacinTablet500mgSDL--
CisplatinConcentrate for Infusion50mg/ 50mLSDL--
Citric Acid Monohydrate & Potassium CitrateOral SolutionCitric Acid Monohydrate 0.25g/ 5mL + Potassium Citrate 1.5g/ 5mLSDL--
ClarithromycinInjection500mgSDL--
ClarithromycinModified-Release Tablet500mgSDL--
ClarithromycinOral Suspension125mg/ 5mLSDL--
ClarithromycinTablet250mgSDL--
ClarithromycinTablet500mgSDL--
Clidinium & ChlordiazepoxideTabletClidinium Bromide 2.5mg + Chlordiazepoxide 5mgSDL--
ClindamycinCapsule150mgSDL--
ClindamycinInjection150mg/ mLSDL--
ClomipheneTablet50mgSDL--
ClomipramineTablet25mgSDL--
ClonazepamTablet0.5mgSDL--
ClonazepamTablet2mgSDL--
ClopidogrelTablet75mgSDL--
ClotrimazoleCream1%SDL--
ClotrimazoleLotion1%SDL--
ClotrimazolePowder1%SDL--
ClotrimazoleVaginal Tablet100mgSDL--
CloxacillinCapsule250mgSDL--
CloxacillinInjection250mgSDL--
CloxacillinInjection500mgSDL--
CloxacillinSyrup125mg/ 5mLSDL--
ClozapineTablet25mgSDL--
ClozapineTablet100mgSDL--
Coal TarCream5%SDL--
Coal TarCream10%SDL--
Coal TarCream15%SDL--
Coal TarLotion20%SDL--
Coal TarShampoo25%SDL--
Coal Tar & Salicylic AcidOintmentCoal Tar 5% + Salicylic acid 2%SDL--
Coal Tar & Salicylic AcidOintmentCoal Tar 10% + Salicylic acid 2%SDL--
Coal Tar & Salicylic AcidOintmentCoal Tar 15% + Salicylic acid 2%SDL--
CocaineSolution 10%SDL--
Cocois CompoundOintmentCoal Tar Solution 10% + Camphor 2% + Sulphur 4% + Salicylic Acid 2%SDL--
Codeine & PromethazineSyrupCodeine Phosphate 18 mg/ 10mL + Promethazine 7.2 mg/ 10mLSDL--
Codeine PhosphateTablet30mgSDL--
Codeine PhosphateTablet30mgSDL--
ColchicineTablet500mcgSDL--
ColecalciferolTablet1000unitsSDL--
ColestyraminePowder For Oral Suspension4gSDL--
Compound DiphenhydramineSyrup5mg/ 5mLSDL--
Compound DiphenhydramineSyrup10mg/ 5mLSDL--
Compound Polyethylene GlycolOral Powder--SDL--
Compound Sodium LactateInfusion-- SDL--
Conjugated OestrogensTablet0.3mgSDL--
Conjugated OestrogensTablet0.625mgSDL--
Conjugated OestrogensVaginal Cream0.625mg/ gSDL--
Conjugated Oestrogens & L-NorgestrelTabletConjugated Oestrogens 625mcg + Norgestrel 150mcgSDL--
CyanocobalaminInjection1mg/ mLSDL--
CyclophosphamideInfusion200mgSDL--
CyclophosphamideInfusion1gSDL--
CyclophosphamideTablet50mgSDL--
CyproheptadineTablet4mgSDL--
CytarabineInjection20mg/ mLSDL--
CytarabineInjection100mg/ mLSDL--
Active Ingredient(s) Dosage Form Strength Subsidy Class Clinical Indication (where applicable)
DacarbazineInjection200mgSDL--
DactinomycinInfusion500mcgSDL--
Dantrolene SodiumCapsule25mgSDL--
Dantrolene SodiumCapsule100mgSDL--
DapagliflozinTablet5mgMAF1) Treatment of type 2 diabetes mellitus, as a dual therapy
  • in combination with metformin for patients with HbA1c > 7% despite treatment with metformin monotherapy and when sulfonylureas are contraindicated, not tolerated, or the person is at significant risk of hypoglycaemia;
  • in combination with a sulfonylurea for patients with HbA1c > 7% despite treatment with sulfonylurea monotherapy and when metformin is contraindicated or not tolerated;
2) Treatment of type 2 diabetes mellitus as a triple therapy
  • in combination with metformin and a sulfonylurea for patients with HbA1c > 7% despite treatment with optimal doses of dual therapy.
DapagliflozinTablet10mg MAF1) Treatment of type 2 diabetes mellitus, as a dual therapy
  • in combination with metformin for patients with HbA1c > 7% despite treatment with metformin monotherapy and when sulfonylureas are contraindicated, not tolerated, or the person is at significant risk of hypoglycaemia;
  • in combination with a sulfonylurea for patients with HbA1c > 7% despite treatment with sulfonylurea monotherapy and when metformin is contraindicated or not tolerated;
  • 2) Treatment of type 2 diabetes mellitus as a triple therapy
  • in combination with metformin and a sulfonylurea for patients with HbA1c > 7% despite treatment with optimal doses of dual therapy.
DapsoneTablet100mgSDL--
DaunorubicinInjection20mgSDL--
DeferiproneOral Solution100mg/ mLSDL--
DeferiproneTablet500mgSDL--
Deferoxamine MesilateInjection500mgSDL--
Denosumab Prefilled Syringe60mg/ mLMAFTreatment of post-menopausal women with osteoporosis (T-score = -2.5) at high risk of fracture and eGFR > 30 ml/min and who are unable to tolerate or follow the administration instructions for oral bisphosphonates.
Dequalinium ChlorideLozenge0.25 mgSDL--
Desmopressin AcetateNasal Drops0.1mg/ mLSDL--
Desmopressin AcetateNasal Spray10mcg/ doseSDL--
Desmopressin AcetateTablet0.1mgSDL--
Desmopressin AcetateTablet0.2mgSDL--
DexamethasoneTablet500mcgSDL--
DexamethasoneTablet4mgSDL--
Dexamethasone PhosphateInjection4mg/ mLSDL--
DexmedetomidineConcentrate for Infusion200mcg/ 2mLSDL--
Dextromethorphan HydrobromideSyrup15mg/ 5mLSDL--
Dextromethorphan HydrobromideTablet15mgSDL--
Dextrose & Sodium ChlorideInfusionDextrose 2.5% + Sodium Chloride 0.45%SDL--
Dextrose & Sodium ChlorideInfusionDextrose 3.75% + Sodium Chloride 0.23%SDL--
Dextrose & Sodium ChlorideInfusionDextrose 5% + Sodium Chloride 0.9% SDL--
Dextrose MonohydrateInfusion5%SDL--
Dextrose MonohydrateInfusion10%SDL--
Dextrose MonohydrateInfusion20%SDL--
Dextrose MonohydrateInfusion50%SDL--
DiazepamEnema5mg/ 2.5mLSDL--
DiazepamInjection5mg/ mLSDL--
DiazepamTablet2mgSDL--
DiazepamTablet5mgSDL--
DiazepamTablet10 mgSDL--
DiazoxideInjection15mg/ mLSDL--
Dibasic Sodium Phosphate & Monobasic Sodium PhosphateEnemaDibasic Sodium Phosphate 7g/ 118mL + Monobasic Sodium Phosphate 19g/ 118mLSDL--
Diclofenac SodiumEnteric-Coated Tablet25mgSDL--
Diclofenac SodiumEnteric-Coated Tablet50mgSDL--
Diclofenac SodiumInjection25mg/ mLSDL--
Diclofenac SodiumRectal Suppository12.5mgSDL--
Diclofenac SodiumRectal Suppository25mgSDL--
Diclofenac SodiumRectal Suppository50mgSDL--
Diclofenac SodiumGel1.00%SDL--
Dicobalt EdetateInjection15mg/ mLSDL--
Diethylcarbamazine CitrateTablet50mgSDL--
DigoxinInjection100mcg/ mLSDL--
DigoxinInjection250mcg/ mL SDL--
DigoxinOral Solution50mcg/ mLSDL--
DigoxinTablet62.5mcgSDL--
DigoxinTablet250mcgSDL--
Digoxin-specific Antibody FragmentsInjection40mgSDL--
Diltiazem HydrochlorideInjection50mgSDL--
Diltiazem HydrochlorideSustained-Release Capsule90mgSDL--
Diltiazem HydrochlorideSustained-Release Capsule100mgSDL--
Diltiazem HydrochlorideSustained-Release Capsule200mgSDL--
Diltiazem HydrochlorideTablet30mgSDL--
Diltiazem HydrochlorideTablet60mgSDL--
DimercaprolInjection50mg/ mLSDL--
Diosmin & HesperidinTabletDiosmin 450mg + Hesperidin 50mgSDL--
Diphenoxylate & Atropine SulfateTabletDiphenoxylate Hydrochloride 2.5mg + Atropine Sulfate 25mcgSDL--
Diphtheria & Tetanus VaccineInjectionDiphtheria Toxoid Vaccine minimum 2 international unit/ 0.5mL + Tetanus Toxoid Vaccine minimum 20 international unit/ 0.5mLSDL--
Diphtheria AntitoxinInjection10,000 unit SDL--
Diphtheria, Tetanus & Pertussis VaccineInjectionDiphtheria Toxoid Vaccine minimum 30 international unit/ 0.5mL + Tetanus Toxoid Vaccine minimum 40 international unit/ 0.5mL + Pertussis Toxoid Vaccine 25 microgram/ 0.5mL + Filamentous Haemagglutinin 25 microgram/ 0.5mL + Pertactin 8 microgram/ 0.5mLSDL--
DipyridamoleTablet25mgSDL--
DipyridamoleTablet75mgSDL--
Disodium EdetateEye Drops0.38%SDL--
Disodium EdetateEye Drops3%SDL--
DithranolOintment1%SDL--
DithranolOintment2%SDL--
DobutamineConcentrate for Infusion250mg/ 5mLSDL--
DobutamineConcentrate for Infusion250mg/ 20mLSDL--
DocetaxelInfusion20mgMAF1) For the treatment of patients with locally advanced or metastatic breast cancer
2) In combination with doxorubicin and cyclophosphamide for the adjuvant treatment of patients with operable node-positive or operable node-negative breast cancer
3) For the treatment of patients with locally advanced or metastatic non-small cell lung cancer
4) In combination with prednisone or prednisolone for the treatment of patients with hormone refractory metastatic prostate cancer
DocetaxelInfusion80mgMAF1) For the treatment of patients with locally advanced or metastatic breast cancer
2) In combination with doxorubicin and cyclophosphamide for the adjuvant treatment of patients with operable node-positive or operable node-negative breast cancer
3) For the treatment of patients with locally advanced or metastatic non-small cell lung cancer
4) In combination with prednisone or prednisolone for the treatment of patients with hormone refractory metastatic prostate cancer
DocetaxelInfusion160mgMAF1) For the treatment of patients with locally advanced or metastatic breast cancer
2) In combination with doxorubicin and cyclophosphamide for the adjuvant treatment of patients with operable node-positive or operable node-negative breast cancer
3) For the treatment of patients with locally advanced or metastatic non-small cell lung cancer
4) In combination with prednisone or prednisolone for the treatment of patients with hormone refractory metastatic prostate cancer
Donepezil HydrochlorideTablet5mgSDL--
Donepezil HydrochlorideTablet10mgSDL--
Donepezil HydrochlorideOral Disintegrating Tablet5mgMAFFor patients with mild to moderately severe Alzheimer's Disease who have swallowing difficulties and are unable to receive a film-coated tablet
Donepezil HydrochlorideOral Disintegrating Tablet10mgMAFFor patients with mild to moderately severe Alzheimer's Disease who have swallowing difficulties and are unable to receive a film-coated tablet
Dopamine HydrochlorideConcentrate for Infusion200mg/ 5mLSDL--
Dothiepin HydrochlorideTablet75mgSDL--
Dothiepin HydrochlorideCapsule25mgSDL--
Doxorubicin HydrochlorideInjection10mgSDL--
Doxorubicin HydrochlorideInjection50mgSDL--
DoxycyclineCapsule100mgSDL--
DroperidolInjection2.5mg/ mLSDL--
DroperidolInjection5mg/ 2mLSDL--
DydrogesteroneTablet10mgSDL--
Active Ingredient(s) Dosage Form Strength Subsidy Class Clinical Indication (where applicable)
Emulsifying OintmentOintment--SDL--
Enalapril MaleateTablet5mgSDL--
Enalapril MaleateTablet10mgSDL--
Enalapril MaleateTablet20mgSDL--
EntacaponeTablet200mgSDL--
EntecavirOral Solution0.05mg/ mLMAFTreatment of nucleos(t)ide-naïve patients with HBeAg-positive and HBeAg-negative chronic hepatitis B infection and evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease
EntecavirTablet0.5mgMAFTreatment of nucleos(t)ide-naïve patients with HBeAg-positive and HBeAg-negative chronic hepatitis B infection and evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease
EntecavirTablet1mgMAFTreatment of nucleos(t)ide-naïve patients with HBeAg-positive and HBeAg-negative chronic hepatitis B infection and evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease
Ephedrine SulfateInjection30mg/ mLSDL--
Epoetin AlfaInjection 2,000 international unit/ 0.5mLSDL--
Epoetin AlfaInjection 4,000 international unit/ 0.4mLSDL--
Epoetin BetaInjection2,000 international unit/ 0.3mLSDL--
Epoetin BetaInjection4,000 international unit/ 0.3mLSDL--
Ergometrine MaleateInjection500mcg/ mLSDL--
Ergotamine & CaffeineTabletCaffeine 100mg + Ergotamine Tartrate 1mgSDL--
Erythromycin (as Ethyl Succinate)Oral Suspension200mg/ 5mLSDL--
Erythromycin (as Ethyl Succinate)Tablet400mgSDL--
Erythromycin (as Lactobionate)Infusion500mgSDL--
Erythromycin (as Lactobionate)Infusion1gSDL--
Erythromycin StearateEnteric-Coated Tablet250mg SDL--
EstradiolVaginal Tablet25mcgSDL--
EstradiolVaginal Tablet10mcgSDL--
EtanerceptPrefilled Syringe25mg/ 0.5mLMAF1) Treatment of adult patients with rheumatoid arthritis
2) Treatment of adult patients with psoriatic arthritis
3) Treatment of adult patients with ankylosing spondylitis
4) Treatment of adult patients with non-radiographic axial spondyloarthritis
5) Treatment of adult patients with chronic plaque psoriasis
6) Treatment of juvenile idiopathic arthritis
EtanerceptPrefilled Syringe50mg/ mLMAF1) Treatment of adult patients with rheumatoid arthritis
2) Treatment of adult patients with psoriatic arthritis
3) Treatment of adult patients with ankylosing spondylitis
4) Treatment of adult patients with non-radiographic axial spondyloarthritis
5) Treatment of adult patients with chronic plaque psoriasis
6) Treatment of juvenile idiopathic arthritis
EtanerceptInjection25mg/ mLMAF1) Treatment of adult patients with rheumatoid arthritis
2) Treatment of adult patients with psoriatic arthritis
3) Treatment of adult patients with ankylosing spondylitis
4) Treatment of adult patients with non-radiographic axial spondyloarthritis
5) Treatment of adult patients with chronic plaque psoriasis
6) Treatment of juvenile idiopathic arthritis
Ethambutol HydrochlorideTablet100mgSDL--
Ethambutol HydrochlorideTablet400mgSDL--
EthanolSolutionEthanol 95%SDL--
EthionamideTablet125mgSDL--
Ethyl ChlorideTopical Spray88g/ 100mLSDL--
EtoposideCapsule50mgSDL--
EtoposideCapsule100mgSDL--
EtoposideConcentrate for Infusion20mg/ mL SDL--
EverolimusTablet0.25mgMAFFor kidney transplant immunosuppression in patients with:
1) Evidence of CNI-induced nephrotoxicity on allograft biopsy OR
2) Elevated serum creatinine levels precluding the achievement of optimal therapeutic blood levels of CNI OR
3) History of CNI drug hypersensitivity
EverolimusTablet0.75mgMAFFor kidney transplant immunosuppression in patients with:
1) Evidence of CNI-induced nephrotoxicity on allograft biopsy OR
2) Elevated serum creatinine levels precluding the achievement of optimal therapeutic blood levels of CNI OR
3) History of CNI drug hypersensitivity
Active Ingredient(s) Dosage Form Strength Subsidy Class Clinical Indication (where applicable)
FamotidineTablet20mgSDL--
FenofibrateCapsule100mgSDL--
FenofibrateCapsule300mgSDL--
FentanylInjection50mcg/ mLSDL--
FentanylTransdermal Patch12mcg/ hrSDL--
FentanylTransdermal Patch25mcg/ hrSDL--
FentanylTransdermal Patch50mcg/ hrSDL--
Ferrous FumarateTablet200mgSDL--
Ferrous GluconateTablet300mgSDL--
Ferrous Gluconate, Multivitamins & MineralsCapsuleFerrous Gluconate 250mg + Vit B12 7.5mcg + Vit C 50mg + Folic Acid 1 mg + Sorbitol 25mg + Copper Sulfate 200mcg + Manganese Sulfate 200mcgSDL--
Ferrous Sulphate & Vitamin B1 & Riboflavin & NicotinamideTabletFerrous sulphate 200mg + Vitamin B1 3mg + Riboflavin 1.5mg + Nicotinamide 10mgSDL--
FilgrastimInjection30 million unit/ 0.5mL (300mcg/ 0.5mL)SDL--
FilgrastimInjection30 million unit/ mL (300mcg/ mL)SDL--
FinasterideTablet5mgSDL--
FluconazoleCapsule50mgSDL--
FluconazoleCapsule100mgSDL--
FluconazoleCapsule150mgSDL--
FluconazoleInfusion100mg/ 50mlSDL--
Fludrocortisone AcetateTablet0.1mgSDL--
FlumazenilInjection0.1mg/ mLSDL--
Fluocinolone AcetonideCream0.0125%SDL--
Fluocinolone AcetonideCream0.0625%SDL--
Fluocinolone AcetonideCream0.025%SDL--
Fluorescein SodiumInjection10%SDL--
Fluorescein SodiumSingle-Use Eye Drops2%SDL--
FluorouracilInjection50mg/ mLSDL--
FluoxetineCapsule10mgSDL--
FluoxetineCapsule20mgSDL--
Flupenthixol DecanoateInjection20mg/ mLSDL--
Flupenthixol DecanoateInjection40mg/ 2mLSDL--
Fluphenazine DecanoateInjection25mg/ mLSDL--
Fluticasone PropionateInhaler50mcg/ doseSDL--
Fluticasone PropionateInhaler125mcg/ doseSDL--
Fluticasone PropionateInhaler250mcg/ doseSDL--
Fluvoxamine MaleateTablet50mg SDL--
Folic AcidTablet5mgSDL--
Folinic AcidInjection10mg/ mLSDL--
Formoterol & BudesonidePowder InhalerFormoterol Fumarate Dihydrate 4.5mcg/ dose + Budesonide 160mcg/ dose SDL--
Formoterol & BudesonidePowder InhalerFormoterol Fumarate Dihydrate 9mcg/ dose + Budesonide 320mcg/ dose SDL--
FurosemideInjection10mg/ mLSDL--
FurosemideTablet40mgSDL--
Active Ingredient(s) Dosage Form Strength Subsidy Class Clinical Indication (where applicable)
GabapentinCapsule100mgSDL--
GabapentinCapsule300mgSDL--
GabapentinCapsule400mgSDL--
GanciclovirInfusion500mgSDL--
Gelatin Succinylated & Sodium ChlorideInfusionGelatin Succinylated 4g/ 100mL + Sodium Chloride 0.701g/ 100mLSDL--
GemcitabineInfusion200mgSDL--
GemcitabineInfusion1000mgSDL--
GemcitabineInfusion2000mgSDL--
GemfibrozilCapsule300mgSDL--
GentamicinInjection40mg/ mLSDL--
GentamicinEye Drops0.30%SDL--
Gentian VioletPaint0.50%SDL--
GlibenclamideTablet5mgSDL--
GliclazideTablet80mgSDL--
GlipizideTablet5mgSDL--
GlucagonInjection1mgSDL--
GlycerolRectal Suppository1gSDL--
GlycerolRectal Suppository1.5gSDL--
GlycerolRectal Suppository2gSDL--
Glycerol, Methyl Salicylate, Sodium Salicylate & Thymol CompoundMouth WashGlycerol 10% + Methyl Salicylate 0.03% + Sodium Salicylate 0.52% + Thymol 0.05%SDL--
Glyceryl TrinitrateOral Spray0.4mg/ doseSDL--
Glyceryl TrinitratePatch5mgSDL--
Glyceryl TrinitratePatch10mgSDL--
Glyceryl TrinitrateSublingual Tablet0.5mgSDL--
GlycineIrrigation Solution1.50%SDL--
GolimumabPrefilled Pen50mg/ 0.5 mLMAF1) Treatment of adult patients with rheumatoid arthritis
2) Treatment of adult patients with psoriatic arthritis
3) Treatment of adult patients with ankylosing spondylitis
4) Treatment of adult patients with ulcerative colitis
5) Treatment of adult patients with non-radiographic axial spondyloarthritis
GolimumabPrefilled Syringe50mg/ 0.5 mLMAF1) Treatment of adult patients with rheumatoid arthritis
2) Treatment of adult patients with psoriatic arthritis
3) Treatment of adult patients with ankylosing spondylitis
4) Treatment of adult patients with ulcerative colitis
5) Treatment of adult patients with non-radiographic axial spondyloarthritis
GoserelinSubcutaneous Injectable Implant3.6mgMAFLHRH agonist is recommended:
1) As primary therapy for men with locally advanced or metastatic prostate cancer
2) As neoadjuvant therapy, for 3 months to 2 years, in men receiving radical radiotherapy
3) For men with prostate cancer who have a biochemical relapse
LHRH agonist is not recommended as monotherapy in patients with low risk prostate cancer
GoserelinSubcutaneous Injectable Implant10.8mgMAFLHRH agonist is recommended:
1) As primary therapy for men with locally advanced or metastatic prostate cancer
2) As neoadjuvant therapy, for 3 months to 2 years, in men receiving radical radiotherapy
3) For men with prostate cancer who have a biochemical relapse
LHRH agonist is not recommended as monotherapy in patients with low risk prostate cancer
GriseofulvinTablet125mgSDL--
GriseofulvinTablet500mgSDL--
GuaifenesinSyrup100mg/ 5mLSDL--
Haemodialysis Concentrate 35X (Acetate Salt)SolutionThe diluted solution contains: Na+ 140.0mmol/ L, K+ 2.60mmol/ L, Ca2+ 1.38mmol/ L, Mg2+ 0.62mmol/ L, Cl- 102mmol/ L, HCO3- 45mmol/ L SDL--
Haemodialysis Concentrate 35X (Bicarbonate)Solution (comprised 2 separate 10L canisters: acidic & basic)Acidic concentrate: KCl 5.5g/ L, NaCl 161.0g/ L, CaCl2.2H2O 9.7g/ L, MgCl2.6H2O 3.7g/ L, CH3COOH (glacial) 8.8g/ L Basic concentrate: NaCl 30.5g/ L, HCO3- 66.0g/ L Final diluted solution contains: Na+ 140mmol/ L, K+ 2.0mmol/ L, Ca2+ 1.8mmol/ L, Mg2+ 0.5mmol/ L, Cl- 107.2mmol/ L, CH3COO- 4.0mmol/ L, HCO3- 35.0mmol/ LSDL--
Active Ingredient(s) Dosage Form Strength Subsidy Class Clinical Indication (where applicable)
HaloperidolInjection5mg/ mLSDL--
HaloperidolOral Solution2mg/ mLSDL--
HaloperidolTablet0.5mgSDL--
HaloperidolTablet1.5mgSDL--
HaloperidolTablet5mgSDL--
Heparin SodiumInjection1,000 unit/ mLSDL--
Heparin SodiumInjection5,000 unit/ mLSDL--
Heparin SodiumInjection25,000 unit/ 5mLSDL--
Heparinised SalineInjection (in sodium chloride 0.9%, preservative-free)50 international unit/ 5 mLSDL--
Hepatitis B ImmunoglobulinInjection1,000 international unit/ 5mLSDL--
Hepatitis B ImmunoglobulinInjection500 unit/ 5mLSDL--
Homatropine HydrobromideEye Drops2%SDL--
Hydralazine HydrochlorideInjection20mg/ mLSDL--
Hydralazine HydrochlorideTablet10mgSDL--
Hydralazine HydrochlorideTablet25mgSDL--
Hydralazine HydrochlorideTablet50mgSDL--
HydrochlorothiazideTablet25mgSDL--
HydrocolloidDressing--SDL--
HydrocolloidGel--SDL--
HydrocortisoneCream0.50%SDL--
HydrocortisoneCream1%SDL--
HydrocortisoneLotion0.50%SDL--
HydrocortisoneOintment1%SDL--
HydrocortisoneTablet10mgSDL--
Hydrocortisone & UreaCreamHydrocortisone 1% + Urea 5%SDL--
Hydrocortisone (as Sodium Succinate)Injection100mgSDL--
Hydrocortisone AcetateRectal Enema100mg/ 100mLSDL--
Hydrocortisone AcetateRectal Enema200mg/ 100mLSDL--
Hydrocortisone Acetate & ClioquinolCreamHydrocortisone Acetate 1% + Clioquinol 3%SDL--
Hydrogen PeroxideMouth Wash3%SDL--
Hydrogen PeroxideTopical Solution3%SDL--
Hydroxychloroquine SulphateTablet200mgSDL--
Hydroxychloroquine SulphateTablet200mgSDL--
Hydroxyprogesterone CaporateInjection250mg/ mLSDL--
HydroxyureaCapsule500mgSDL--
Hydroxyzine HydrochlorideSyrup10mg/ 5mLSDL--
Hydroxyzine HydrochlorideTablet10mgSDL--
Hydroxyzine HydrochlorideTablet25mgSDL--
Hyoscine ButylbromideInjection20mg/ mLSDL--
Hyoscine ButylbromideTablet10mgSDL--
Hyoscine Hydrobromide TrihydrateInjection400mcg/ mLSDL--
Hyoscine Hydrobromide TrihydrateInjection400mcg/ mLSDL--
HypromelloseEye Drops0.30%SDL--
Active Ingredient(s) Dosage Form Strength Subsidy Class Clinical Indication (where applicable)
IbuprofenOral Liquid100mg/ 5mLSDL--
IbuprofenTablet200 mgSDL--
IfosfamideInfusion1gSDL--
Imipenem & CilastatinInfusionImipenem 500mg + Cilastatin 500mgSDL--
Imipramine HydrochlorideTablet10mgSDL--
Imipramine HydrochlorideTablet25mgSDL--
IndometacinCapsule25mgSDL--
Infliximab (Remicade)Injection100mgMAF1) Treatment of adult patients with rheumatoid arthritis
2) Treatment of adult patients with psoriatic arthritis
3) Treatment of adult patients with ankylosing spondylitis
4) Treatment of adult patients with Crohn's disease
5) Treatment of children (6 to 17 years) with Crohn's disease
6) Treatment of adult patients with ulcerative colitis
7) Treatment of children (6 to 17 years) with ulcerative colitis
8) Treatment of adult patients with chronic plaque psoriasis
Infliximab (Remsima)Infusion100mgMAF1) Treatment of adult patients with rheumatoid arthritis
2) Treatment of adult patients with psoriatic arthritis
3) Treatment of adult patients with ankylosing spondylitis
4) Treatment of adult patients with Crohn's disease
5) Treatment of children (6 to 17 years) with Crohn's disease
6) Treatment of adult patients with ulcerative colitis
7) Treatment of children (6 to 17 years) with ulcerative colitis
8) Treatment of adult patients with chronic plaque psoriasis
Insulin AspartInjection, Penfill100 international unit/ mLMAFType 1 & 2 diabetes mellitus
Insulin AspartInjection, Prefilled Pen100 international unit/ mLMAFType 1 & 2 diabetes mellitus
Insulin Aspart & Insulin Aspart ProtamineInjection, Prefilled PenInsulin Aspart 30 international unit/ mL + Insulin Aspart Protamine 70 international unit/ mLMAFType 1 & 2 diabetes mellitus
Insulin DetemirInjection, Prefilled Pen100 international unit/ mLSDL--
Insulin Glargine (Basaglar)Injection, Cartridge100 international unit/ mLSDL--
Insulin Glargine (Lantus)Injection100 international unit/ mLSDL--
Insulin Glargine (Lantus)Injection, Penfill100 international unit/ mLSDL--
Insulin Glargine (Lantus)Injection, Prefilled Pen100 international unit/ mLSDL--
Insulin GlulisineInjection, Prefilled Pen100 international unit/ mLSDL--
Insulin Isophane (Human)Injection100 international unit/ mLSDL--
Insulin Isophane (Human)Injection, Penfill100 international unit/ mLSDL--
Insulin LisproInjection100 international unit/ mLMAFType 1 & 2 diabetes mellitus
Insulin LisproInjection, Penfill100 international unit/ mLMAFType 1 & 2 diabetes mellitus
Insulin LisproInjection, Prefilled Pen100 international unit/ mLMAFType 1 & 2 diabetes mellitus
Insulin Lispro & Insulin Lispro ProtamineInjection, PenfillInsulin Lispro 25% + Insulin Lispro Protamine 75% SDL--
Insulin Lispro & Insulin Lispro ProtamineInjection, Prefilled PenInsulin Lispro 25% + Insulin Lispro Protamine 75% MAFType 1 & 2 diabetes mellitus
Insulin Lispro & Insulin Lispro ProtamineInjection, Prefilled PenInsulin Lispro 50% + Insulin Lispro Protamine 50% MAFType 1 & 2 diabetes mellitus
Insulin Soluble & Insulin Isophane (Human)InjectionInsulin Soluble 30% + Insulin Isophane 70%SDL--
Insulin Soluble & Insulin Isophane (Human)Injection, PenfillInsulin Soluble 30% + Insulin Isophane 70%SDL--
Insulin Soluble (Human)Injection100 international unit/ mL SDL--
Insulin Soluble (Human)Injection, Penfill100 international unit/ mLSDL--
Insulin, Zinc Suspension (Human)Injection100 international unit/ mLSDL--
Intraperitoneal DialysisSolutionDextrose 1.5%, 2.5% or 4.25% with Ca2+ 1.25mmol/ L, Na+ 132mmol/ L, Mg2+ 0.25mmol/ L, Cl- 95mmol/ L, Lactate 40mmol/ LSDL--
Intraperitoneal DialysisSolutionDextrose 1.5%, 2.5% or 4.25% with Ca2+ 2.57mmol/ L, Na+ 132mmol/ L, Mg2+ 0.25mmol/ L, Cl- 96mmol/ L, Lactate 40mmol/ LSDL--
IodineTopical Solution0.50%SDL--
IodineTopical Solution0.50%SDL--
IodineTopical Solution1.00%SDL--
IodineTopical Solution2.50%SDL--
Iodine AqueousOral SolutionIodine 5% + Potassium iodide 10% SDL--
IpecacuanhaSuspensionIpecacuanha Ext 7%SDL--
Ipratropium BromideInhaler20mcg/ doseSDL--
Ipratropium BromideNebulisation Solution0.03%SDL--
Irinotecan Hydrochloride TrihydrateInfusion20mg/ mL SDL--
Iron (as Polymaltose)Oral Drops50mg/ mLSDL--
Iron (as Sucrose)Injection100mg/ 5mLSDL--
IsoniazidTablet100mgSDL--
IsoniazidTablet300mgSDL--
Isoprenaline HydrochlorideInjection0.2mg/ mLSDL--
Isoprenaline HydrochlorideInjection1mg/ mLSDL--
Isoprenaline SulfateInjection0.2mg/ mLSDL--
Isoprenaline SulfateInjection1mg/ mLSDL--
Isosorbide DinitrateSublingual Tablet5mgSDL--
Isosorbide DinitrateTablet10mgSDL--
Isosorbide MononitrateSustained-Release Tablet60mgSDL--
ItraconazoleOral Solution10mg/ mLMAFFor prophylaxis of invasive fungal infections in high risk patients (such as anticipated to have prolonged neutropenia) and haematopoietic stem cell transplant recipients.
ItraconazoleCapsule100mgSDL--
IvabradineTablet5mgMAFTreatment of chronic heart failure in patients with New York Heart Association (NYHA) class II to IV stable chronic heart failure with systolic dysfunction (LVEF of 35% or less), and who are in sinus rhythm with a heart rate of 75 bpm or more, and who are given concomitant standard medical management including the maximum tolerated dose of beta-blocker therapy, angiotensin converting enzyme inhibitors and aldosterone antagonists, unless contraindicated or not tolerated.
IvabradineTablet7.5mgMAFTreatment of chronic heart failure in patients with New York Heart Association (NYHA) class II to IV stable chronic heart failure with systolic dysfunction (LVEF of 35% or less), and who are in sinus rhythm with a heart rate of 75 bpm or more, and who are given concomitant standard medical management including the maximum tolerated dose of beta-blocker therapy, angiotensin converting enzyme inhibitors and aldosterone antagonists, unless contraindicated or not tolerated.
Active Ingredient(s) Dosage Form Strength Subsidy Class Clinical Indication (where applicable)
KanamycinInjection1gSDL--
KanamycinInjection1gSDL--
Kaolin, Magnesium Carbonate (light) & Sodium BicarbonateOral SuspensionKaolin 20% + Magnesium Carbonate (light) 5% + Sodium Bicarbonate 5%SDL--
KetoprofenEnteric-Coated Tablet100mgSDL--
KetoprofenSlow-Release Tablet200mgSDL--
KetoprofenGel2.50%SDL--
Active Ingredient(s) Dosage Form Strength Subsidy Class Clinical Indication (where applicable)
LactuloseSyrup3.3g/ 5mLSDL--
LactuloseSyrup3.35g/ 5mLSDL--
LamivudineTablet 100mgSDL--
LamotrigineDispersible Tablet5mgSDL--
LamotrigineTablet50mgSDL--
LamotrigineTablet100mgSDL--
Land Snakes AntivenomConcentrate for Infusion--SDL--
L-AsparaginaseInjection10,000 international unitSDL--
LeflunomideTablet10mgMAF1) Treatment of active psoriatic arthritis where other disease modifying drugs are ineffective and/ or inappropriate
2) Treatment of active rheumatoid arthritis where other disease modifying drugs are ineffective and/ or inappropriate
LeflunomideTablet20mgMAF1) Treatment of active psoriatic arthritis where other disease modifying drugs are ineffective and/ or inappropriate
2) Treatment of active rheumatoid arthritis where other disease modifying drugs are ineffective and/ or inappropriate
LeflunomideTablet100mgMAF1) Treatment of active psoriatic arthritis where other disease modifying drugs are ineffective and/ or inappropriate
2) Treatment of active rheumatoid arthritis where other disease modifying drugs are ineffective and/ or inappropriate
LetrozoleTablet2.5mgSDL--
Leuprorelin AcetateInjection3.75mgMAFLHRH agonist is recommended:
1) As primary therapy for men with locally advanced or metastatic prostate cancer
2) As neoadjuvant therapy, for 3 months to 2 years, in men receiving radical radiotherapy
3) For men with prostate cancer who have a biochemical relapse
LHRH agonist is not recommended as monotherapy in patients with low risk prostate cancer
Leuprorelin AcetateInjection11.25mgMAFLHRH agonist is recommended:
1) As primary therapy for men with locally advanced or metastatic prostate cancer
2) As neoadjuvant therapy, for 3 months to 2 years, in men receiving radical radiotherapy
3) For men with prostate cancer who have a biochemical relapse
LHRH agonist is not recommended as monotherapy in patients with low risk prostate cancer
Leuprorelin AcetateInjection30mgMAFLHRH agonist is recommended:
1) As primary therapy for men with locally advanced or metastatic prostate cancer
2) As neoadjuvant therapy, for 3 months to 2 years, in men receiving radical radiotherapy
3) For men with prostate cancer who have a biochemical relapse
LHRH agonist is not recommended as monotherapy in patients with low risk prostate cancer
Leuprorelin AcetateInjection5 mg/ mLMAFLHRH agonist is recommended:
1) As primary therapy for men with locally advanced or metastatic prostate cancer
2) As neoadjuvant therapy, for 3 months to 2 years, in men receiving radical radiotherapy
3) For men with prostate cancer who have a biochemical relapse
LHRH agonist is not recommended as monotherapy in patients with low risk prostate cancer
Leuprorelin AcetateInjection7.5mgMAFLHRH agonist is recommended:
1) As primary therapy for men with locally advanced or metastatic prostate cancer
2) As neoadjuvant therapy, for 3 months to 2 years, in men receiving radical radiotherapy
3) For men with prostate cancer who have a biochemical relapse
LHRH agonist is not recommended as monotherapy in patients with low risk prostate cancer
Leuprorelin AcetateInjection22.5mgMAFLHRH agonist is recommended:
1) As primary therapy for men with locally advanced or metastatic prostate cancer
2) As neoadjuvant therapy, for 3 months to 2 years, in men receiving radical radiotherapy
3) For men with prostate cancer who have a biochemical relapse
LHRH agonist is not recommended as monotherapy in patients with low risk prostate cancer
Leuprorelin AcetateInjection45mgMAFLHRH agonist is recommended:
1) As primary therapy for men with locally advanced or metastatic prostate cancer
2) As neoadjuvant therapy, for 3 months to 2 years, in men receiving radical radiotherapy
3) For men with prostate cancer who have a biochemical relapse
LHRH agonist is not recommended as monotherapy in patients with low risk prostate cancer
LevetiracetamConcentrate for Infusion100mg/ mLMAF1) As a 2nd line agent for the management of epilepsy in adults and children
2) As adjunctive therapy or monotherapy in patients who have inadequate seizure control or intolerable adverse effects with 1st line agents, or where the use of 1st line agents is contraindicated
LevetiracetamOral Solution100mg/ mLMAF1) As a 2nd line agent for the management of epilepsy in adults and children
2) As adjunctive therapy or monotherapy in patients who have inadequate seizure control or intolerable adverse effects with 1st line agents, or where the use of 1st line agents is contraindicated
LevetiracetamTablet250mgMAF1) As a 2nd line agent for the management of epilepsy in adults and children
2) As adjunctive therapy or monotherapy in patients who have inadequate seizure control or intolerable adverse effects with 1st line agents, or where the use of 1st line agents is contraindicated
LevetiracetamTablet500mgMAF1) As a 2nd line agent for the management of epilepsy in adults and children
2) As adjunctive therapy or monotherapy in patients who have inadequate seizure control or intolerable adverse effects with 1st line agents, or where the use of 1st line agents is contraindicated
LevetiracetamTablet1gMAF1) As a 2nd line agent for the management of epilepsy in adults and children
2) As adjunctive therapy or monotherapy in patients who have inadequate seizure control or intolerable adverse effects with 1st line agents, or where the use of 1st line agents is contraindicated
Levodopa & BenserazideCapsuleLevodopa 100mg + Benserazide 25mgSDL--
Levodopa & BenserazideTabletLevodopa 200mg + Benserazide 50mgSDL--
Levodopa & BenserazideControlled-Release CapsuleLevodopa 100 mg + Benserazide 25 mgSDL--
Levodopa & CarbidopaTabletLevodopa 100mg + Carbidopa 25mgSDL--
Levodopa & CarbidopaTabletLevodopa 250mg + Carbidopa 25mgSDL--
Levodopa, Carbidopa & EntacaponeTabletLevodopa 50mg + Carbidopa 12.5mg + Entacapone 200mgSDL--
Levodopa, Carbidopa & EntacaponeTabletLevodopa 100mg+ Carbidopa 25mg + Entacapone 200mgSDL--
Levodopa, Carbidopa & EntacaponeTabletLevodopa 150mg + Carbidopa 37.5mg + Entacapone 200mgSDL--
Levodopa, Carbidopa & EntacaponeTabletLevodopa 200mg + Carbidopa 50mg + Entacapone 200mgSDL--
Levonorgestrel & EthinylestradiolTabletLevonorgestrel 0.15mg + Ethinylestradiol 0.03mgSDL--
Levothyroxine SodiumTablet25mcgSDL--
Levothyroxine SodiumTablet50mcgSDL--
Levothyroxine SodiumTablet75mcgSDL--
Levothyroxine SodiumTablet100mcgSDL--
LidocaineOintment5%SDL--
LidocaineTopical Solution4%SDL--
LidocaineTopical Spray10%SDL--
LidocaineTopical Spray10%SDL--
Lidocaine & AdrenalineInjectionLidocaine 2% + Adrenaline 1:80,000 (12.5 microgram/ mL)SDL--
Lidocaine & PrilocaineCreamLidocaine 2.5% + Prilocaine 2.5%SDL--
Lidocaine HydrochlorideInjection (Preservative free)1%SDL--
Lidocaine HydrochlorideInjection (Preservative free)1.50%SDL--
Lidocaine HydrochlorideInjection (Preservative free)2%SDL--
Lidocaine HydrochlorideInjection (Preservative free)10%SDL--
Lidocaine HydrochlorideGel2%SDL--
Lidocaine HydrochlorideInjection1%SDL--
Lidocaine HydrochlorideInjection10%SDL--
Lidocaine HydrochlorideOral Solution (viscous)2%SDL--
LinagliptinTablet5mgMAFFor patients with type 2 diabetes mellitus and chronic kidney disease stage 3b, 4 or 5
Liothyronine SodiumTablet20mcgSDL--
Liquid ParaffinOral Emulsion2.5mL/ 5mLSDL--
Liquid ParaffinLiquid--SDL--
LisinoprilTablet5mgSDL--
LisinoprilTablet10mgSDL--
LisinoprilTablet20mgSDL--
Lithium CarbonateControlled-Release Tablet400mg SDL--
LomustineCapsule40mgSDL--
LoratadineSyrup5mg/ 5mLSDL--
LoratadineTablet10mgSDL--
LorazepamTablet0.5mgSDL--
LorazepamTablet1mgSDL--
Losartan PotassiumTablet50mgSDL--
Losartan PotassiumTablet100mgSDL--
LovastatinTablet20mgSDL--
Active Ingredient(s) Dosage Form Strength Subsidy Class Clinical Indication (where applicable)
Magnesium Carbonate & Sodium BicarbonateOral SuspensionMagnesium Carbonate 150mg/ 5mL + Sodium Bicarbonate 250mg/ 5mL + Aromatic Cardamon Tincture 0.15mL/ 5mLSDL--
Magnesium Carbonate & Sodium BicarbonateOral SuspensionMagnesium Carbonate 150mg/ 5mL + Sodium Bicarbonate 250mg/ 5mL + Aromatic Cardamon Tincture 0.15mL/ 5mLSDL--
Magnesium Chloride Hexahydrate, Potassium Chloride & Procaine HydrochlorideConcentrate for InfusionMagnesium Chloride Hexahydrate 162.5mg/ mL (0.8mmol/ mL) + Potassium Chloride 59.5 mg/ mL (0.8mmol/ mL) + Procaine Hydrochloride 13.64mg/ mL (0.05mmol/ mL)SDL--
Magnesium SulfateSuspension40%SDL--
Magnesium SulfateInjection49.30%SDL--
Magnesium SulfateInjection49.3% (2mmol Mg2+/ mL)SDL--
Magnesium SulfatePaste38.50%SDL--
Magnesium TrisilicateOral SuspensionMagnesium Trisilicate 5% + Magnesium Carbonate 5% + Sodium Bicarbonate 5% Oral SuspensionSDL--
MalathionLotion0.50%SDL--
MannitolInfusion20%SDL--
Measles, Mumps, Rubella VaccineInjectionMeasles Virus Vaccine (live-attenuated) minimum 1,000 CCID50/ 0.5mL + Mumps Virus Vaccine (live-attenuated) minimum 12,500 CCID50/ 0.5mL + Rubella Virus Vaccine (live-attenuated) minimum 1,000 CCID50/ 0.5mLSDL--
Mebeverine HydrochlorideTablet135mgSDL--
Medroxyprogesterone AcetateInjection50mg/ mLSDL--
Medroxyprogesterone AcetateTablet5mgSDL--
Mefenamic AcidCapsule250mgSDL--
MefloquineTablet250mgSDL--
MelphalanInjection50mgSDL--
MelphalanTablet2mgSDL--
MercaptopurineTablet50mgSDL--
MeropenemInjection500mgSDL--
MeropenemInjection1gSDL--
MesalazineEnema2g/ 30mLSDL--
MesalazineEnteric-Coated Tablet250mgSDL--
MesalazineEnteric-Coated Tablet400mgSDL--
MesalazineEnteric-Coated Tablet500mgSDL--
MesalazineEnteric-Coated Tablet800mgSDL--
MesalazineSlow-Release Tablet500mgSDL--
MesalazineSuppository250mgSDL--
MesalazineSuppository500mg SDL--
MesalazineSuppository1g SDL--
MesnaInjection100mg/ mLSDL--
MesnaTablet400mgSDL--
MesnaTablet600mgSDL--
Metformin HydrochlorideTablet250mgSDL--
Metformin HydrochlorideTablet500mgSDL--
Metformin HydrochlorideTablet850mgSDL--
MethadoneTablet5mgSDL--
MethadoneTablet5mgSDL--
MethionineTablet250mgSDL--
MethionineTablet2.5gSDL--
MethotrexateInjection50mg/ 2mLSDL--
MethotrexateInjection1g/ 10mLSDL--
MethotrexateTablet2.5mgSDL--
MethotrexateInjection (preservative-free)50mg/ 2mL SDL--
MethotrexateTablet2.5mgSDL--
MethoxsalenLotion0.01%SDL--
MethoxsalenLotion0.05%SDL--
MethoxsalenLotion0.10%SDL--
MethoxsalenLotion0.75%SDL--
MethoxsalenCapsule10mgSDL--
MethoxsalenTablet 10mgSDL--
Methyl SalicylateCream10% - 20%SDL--
Methyl SalicylateSolution25%SDL--
Methylated SpiritTopical Solution70%SDL--
Methylated SpiritEar Drops47.50%SDL--
MethyldopaTablet125mgSDL--
MethyldopaTablet250mgSDL--
Methylphenidate HydrochlorideExtended-Release Tablet18mgMAFAttention deficit hyperactivity disorder in children and adolescents aged <18 years old
Methylphenidate HydrochlorideExtended-Release Tablet27mgMAFAttention deficit hyperactivity disorder in children and adolescents aged <18 years old
Methylphenidate HydrochlorideExtended-Release Tablet36mgMAFAttention deficit hyperactivity disorder in children and adolescents aged <18 years old
Methylphenidate HydrochlorideExtended-Release Tablet54mgMAFAttention deficit hyperactivity disorder in children and adolescents aged <18 years old
Methylphenidate HydrochlorideModified-Release Capsule20mgMAFAttention deficit hyperactivity disorder in children and adolescents aged <18 years old
Methylphenidate HydrochlorideSustained-ReleaseTablet20mgMAFAttention deficit hyperactivity disorder in children and adolescents aged <18 years old
Methylphenidate HydrochlorideTablet10mgSDL--
Methylprednisolone (as Sodium Succinate)Injection62.5mg/ mLSDL--
Metoclopramide HydrochlorideInjection5mg/ mLSDL--
Metoclopramide HydrochlorideTablet10mgSDL--
MetronidazoleInfusion5mg/ mLSDL--
MetronidazoleTablet200mgSDL--
MetronidazoleTablet200mgSDL--
MiconazoleOral Gel2%SDL--
Miconazole NitrateCream2%SDL--
MidazolamInjection5mg/ mLSDL--
MidazolamInjection5mg/ 5mLSDL--
Midodrine HydrochlorideTablet5mgSDL--
MirtazapineOral Disintegrating Tablet15mgSDL--
MirtazapineOral Disintegrating Tablet30mgSDL--
MirtazapineTablet30mgSDL--
MitomycinInjection2mgSDL--
MitomycinInjection10mgSDL--
MitoxantroneInjection2mg/ mLSDL--
MoclobemideTablet150mgSDL--
Mometasone FuroateNasal Spray0.05%MAFFor treatment of allergic rhinitis in
1) Children from 2 - 6 years old
2) Children above 6 years to 12 years who are unable to use other alternative intra-nasal steroidal preparation
Morphine SulfateControlled-Release Tablet10mgSDL--
Morphine SulfateControlled-Release Tablet30mgSDL--
Morphine SulfateInjection10mg/ mLSDL--
Morphine SulfateOral Solution10mg/ 5mLSDL--
Morphine SulfateSyrup1mg/ mLSDL--
Multivitamin for PaediatricsOral SolutionAscorbic acid 35mg/ mL + Riboflavine 0.6mg/ mL + Nicotinamide 8mg/ mL + Thiamine 0.5mg/ mL + Pyridoxine 0.4mg/ mL + Calciferol 400 international unit/ mL + Cyanocobalamin 2.0mcg/ mL + Vitamin A 1,500 international unit/ mLSDL--
MydricaineOphthalmic Solution Atropine Sulfate 0.34% + Cocaine HCl 2% + Adrenaline 0.034% + Sodium Chloride 0.26%SDL--
Active Ingredient(s) Dosage Form Strength Subsidy Class Clinical Indication (where applicable)
Nalidixic AcidTablet500mgSDL--
Naloxone HydrochlorideInjection0.4mg/ mLSDL--
Naloxone HydrochlorideInjection0.02 mg/ mLSDL--
Nandrolone DecanoateInjection25mg/ mLSDL--
Naphazoline Hydrochloride & Pheniramine MaleateEye DropsNaphazoline Hydrochloride 0.025% + Pheniramine Maleate 0.3%SDL--
Neomycin SulfateTablet500mgSDL--
Neomycin SulfateTablet500mgSDL--
Neomycin, Polymyxin B & DexamethasoneEar dropsNeomycin Sulfate 6,500 international unit/ mL + Polymyxin B Sulfate 10,000 international unit/ mL + Dexamethasone Sodium Metasulfobenzoate 1 mg/ mLSDL--
Neostigmine MetilsulfateInjection0.5mg/ mLSDL--
Neostigmine MetilsulfateInjection2.5mg/ mLSDL--
Nicotinic AcidTablet50mgSDL--
NifedipineCapsule5mgSDL--
NifedipineCapsule10mgSDL--
NifedipineExtended-Release Tablet30mgSDL--
NifedipineExtended-Release Tablet60mgSDL--
NifedipineTablet5mgSDL--
NifedipineTablet10mgSDL--
NitrazepamTablet5mgSDL--
NitrofurantoinTablet50mgSDL--
NorepinephrineConcentrate for Infusion4mg/ 4mLSDL--
NorethisteroneTablet5mgSDL--
NortriptylineCapsule10mgSDL--
NortriptylineCapsule25mgSDL--
NystatinOral Suspension100,000unit/ mLSDL--
NystatinVaginal Tablet100,000 unitSDL--
Active Ingredient(s) Dosage Form Strength Subsidy Class Clinical Indication (where applicable)
OlanzapineOral Disintegrating Tablet5mgSDL--
OlanzapineOral Disintegrating Tablet10mgSDL--
OlanzapineTablet5mgSDL--
OlanzapineTablet10mgSDL--
Olive OilEar Drops--SDL--
OmeprazoleCapsule20mgSDL--
Oral Rehydration SaltsEffervescent Tablet--SDL--
Oral Rehydration SaltsOral Powder for Reconstitution--SDL--
OxaliplatinConcentrate for Infusion50mg/ 10mLSDL--
OxaliplatinInfusion50mgSDL--
Oxybutynin ChlorideTablet5mgSDL--
Oxymetazoline HydrochlorideNasal Drops0.01%SDL--
Oxymetazoline HydrochlorideNasal Drops0.025%SDL--
Oxymetazoline HydrochlorideNasal Drops0.05%SDL--
Oxymetazoline HydrochlorideNasal Spray0.025%SDL--
Oxymetazoline HydrochlorideNasal Spray0.05%SDL--
OxytocinInjection10 international unit/ mLSDL--
Oxytocin & Ergometrine MaleateInjectionOxytocin 5 international unit/ mL + Ergometrine Maleate 0.5mg/ mLSDL--
Active Ingredient(s) Dosage Form Strength Subsidy Class Clinical Indication (where applicable)
PaclitaxelConcentrate for Infusion6mg/ mLSDL--
Pamidronate DisodiumInfusion30mgMAF1) Treatment of metastatic bone lesions from breast cancer and advanced multiple myeloma.
2) Treatment of hypercalcaemia of malignancy.
Pamidronate DisodiumInfusion90mgMAF1) Treatment of metastatic bone lesions from breast cancer and advanced multiple myeloma.
2) Treatment of hypercalcaemia of malignancy.
Pancuronium BromideConcentrate for Infusion2mg/ mLSDL--
ParacetamolOral Suspension120mg/ 5mLSDL--
ParacetamolRectal Suppository125mgSDL--
ParacetamolRectal Suppository250mgSDL--
ParacetamolRectal Suppository325mgSDL--
ParacetamolRectal Suppository650mgSDL--
ParacetamolTablet120mgSDL--
ParacetamolTablet500mgSDL--
Paracetamol Infusion1,000mg/ 100 mLSDL--
Paracetamol Infusion500mg/ 50 mLSDL--
Paracetamol & Orphenadrine CitrateTabletParacetamol 450mg + Orphenadrine Citrate 35mgSDL--
ParaffinLiquid--SDL--
Paraffin Soft & Paraffin LiquidEmulsionSoft Paraffin 50% + Liquid Paraffin 50%SDL--
ParaldehydeInjection100%SDL--
Peginterferon Alfa-2aInjection135mcg/ 0.5mLMAF1) Treatment, in combination with ribavirin, of chronic hepatitis C infection in naive adult patients and patients who have failed previous treatment with interferon alfa (pegylated or non-pegylated) alone or in combination therapy with ribavirin
2) Treatment for a duration of up to 48 weeks, in adult patients with HBeAg-positive and HBeAg-negative chronic hepatitis B infection with compensated liver disease and evidence of viral replication and liver inflammation.
Peginterferon Alfa-2aInjection180mcg/ 0.5mLMAF1) Treatment, in combination with ribavirin, of chronic hepatitis C infection in naive adult patients and patients who have failed previous treatment with interferon alfa (pegylated or non-pegylated) alone or in combination therapy with ribavirin
2) Treatment for a duration of up to 48 weeks, in adult patients with HBeAg-positive and HBeAg-negative chronic hepatitis B infection with compensated liver disease and evidence of viral replication and liver inflammation.
Peginterferon Alfa-2bInjection50mcg/ 0.5mLMAFTreatment, in combination with ribavirin, of chronic hepatitis C infection in naïve adult patients and patients who have failed previous treatment with interferon alfa (pegylated or non-pegylated) alone or in combination therapy with ribavirin
Peginterferon Alfa-2bInjection80mcg/ 0.5mLMAFTreatment, in combination with ribavirin, of chronic hepatitis C infection in naïve adult patients and patients who have failed previous treatment with interferon alfa (pegylated or non-pegylated) alone or in combination therapy with ribavirin
Peginterferon Alfa-2bInjection100mcg/ 0.5mLMAFTreatment, in combination with ribavirin, of chronic hepatitis C infection in naïve adult patients and patients who have failed previous treatment with interferon alfa (pegylated or non-pegylated) alone or in combination therapy with ribavirin
Peginterferon Alfa-2bInjection120mcg/ 0.5mLMAFTreatment, in combination with ribavirin, of chronic hepatitis C infection in naïve adult patients and patients who have failed previous treatment with interferon alfa (pegylated or non-pegylated) alone or in combination therapy with ribavirin
Peginterferon Alfa-2bInjection150mcg/ 0.5mLMAFTreatment, in combination with ribavirin, of chronic hepatitis C infection in naïve adult patients and patients who have failed previous treatment with interferon alfa (pegylated or non-pegylated) alone or in combination therapy with ribavirin
PenicillamineCapsule250mgSDL--
PentazocineInjection30mg/ mLSDL--
Pethidine HydrochlorideInjection50mg/ mLSDL--
Phenobarbital SodiumInjection20mg/ 0.5mLSDL--
PhenobarbitoneTablet10mgSDL--
PhenobarbitoneTablet30mgSDL--
PhenobarbitoneTablet60mgSDL--
Phenol (in almond oil)Injection5%SDL--
PhenoxymethylpenicillinTablet250mgSDL--
Phenylephrine HydrochlorideEye Drops2.50%SDL--
Phenylephrine HydrochlorideEye Drops10%SDL--
Phenylephrine HydrochlorideSingle-Use Eye Drops2.50%SDL--
Phenylephrine HydrochlorideSingle-Use Eye Drops10%SDL--
PhenytoinOral Suspension125mg/ 5mLSDL--
Phenytoin SodiumCapsule30mgSDL--
Phenytoin SodiumCapsule100mgSDL--
Phenytoin SodiumInjection50mg/ mLSDL--
Phosphate BufferPowder--SDL--
Physostigmine SalicylateInjection1mg/ mLSDL--
PhytomenadioneInjection10mg / mLSDL--
Pilocarpine HydrochlorideEye Drops1%SDL--
Pilocarpine HydrochlorideEye Drops2%SDL--
Pilocarpine HydrochlorideEye Drops4%SDL--
Pilocarpine NitrateSingle-Use Eye Drops2%SDL--
Pine OilInhalationMenthol 7% + Eucalyptus Oil 3% + Peppermint Oil 4% + Pine Oil 2.5%SDL--
Piperacillin & TazobactamInjectionPiperacillin 4g + Tazobactam 0.5gSDL--
Pipotiazine PalmitateInjection50mg/ mLSDL--
PiroxicamCapsule10mgSDL--
PiroxicamCapsule20mgSDL--
PiroxicamGel0.50%SDL--
Podophyllum ResinPaint25%SDL--
Poliomyelitis Vaccine (live-attenuated)Oral SuspensionPoliovirus Vaccine (type 1 live-attenuated) minimum 1,000,000 TCID50/ 0.5mL + Poliovirus Vaccine (type 2 live-attenuated) minimum 100,000 TCID50/ 0.5mL + Poliovirus Vaccine (type 3 live-attenuated) minimum 300,000 TCID50/ 0.5mLSDL--
PosaconazoleOral Suspension40mg/ mLMAFFor prophylaxis of invasive fungal infections in high risk patients (such as anticipated to have prolonged neutropenia) and haematopoietic stem cell transplant recipients.
PosaconazoleDelayed-Release Tablet100mgMAFFor prophylaxis of invasive fungal infections in high risk patients (such as anticipated to have prolonged neutropenia) and haematopoietic stem cell transplant recipients.
Potassium ChlorideSlow-Release Tablet600mgSDL--
Potassium ChlorideConcentrate for Infusion7.45%SDL--
Potassium ChlorideInfusion0.1mmol/ mLSDL--
Potassium CitrateOral Solution500mg/ 5mLSDL--
Potassium PermanganateCrystals100%SDL--
Potassium PermanganateTopical Solution0.10%SDL--
Potassium Phosphate MonobasicConcentrate for Infusion1mmol/ mL (0.1361mg/ mL)SDL--
Povidone-IodineTopical Solution10%SDL--
Pralidoxime ChlorideInjection500mg/ 20mLSDL--
Pramipexole Dihydrochloride MonohydrateTablet0.125mgSDL--
Pramipexole Dihydrochloride MonohydrateTablet1mgSDL--
Pravastatin SodiumTablet20mgSDL--
PrazosinTablet1mgSDL--
PrazosinTablet5mgSDL--
PrazosinTablet1mgSDL--
PrazosinTablet5mgSDL--
PrednisoloneSyrup10mg/ 5mLSDL--
PrednisoloneTablet1mgSDL--
PrednisoloneTablet5mgSDL--
PrednisoloneTablet20mgSDL--
PrimaquineTablet7.5mgSDL--
ProbenecidTablet500mgSDL--
Procainamide HydrochlorideInjection100mg/ mLSDL--
Procainamide HydrochlorideSustained-Release Tablet500mg SDL--
Procaine HydrochlorideLotion (in spirit 70%)2%SDL--
ProcarbazineCapsule50mgSDL--
Prochlorperazine MaleateTablet5mgSDL--
Prochlorperazine MaleateTablet5mgSDL--
Prochlorperazine MesilateInjection12.5mg/ mLSDL--
Prochlorperazine MesilateInjection12.5mg/ mLSDL--
ProgesteroneInjection50mg/ mLSDL--
Promethazine HydrochlorideSyrup5mg/ 5mLSDL--
Promethazine HydrochlorideTablet25mgSDL--
Promethazine HydrochlorideInjection25mg/ mLSDL--
Promethazine HydrochlorideSyrup5mg/ 5mLSDL--
Promethazine TheoclateTablet25mgSDL--
Propantheline BromideTablet15mgSDL--
Propantheline BromideTablet15mgSDL--
Proparacaine HydrochlorideEye Drops0.50%SDL--
PropofolInjection10mg/ mLSDL--
Propranolol HydrochlorideInjection1mg/ mLSDL--
Propranolol HydrochlorideTablet10mgSDL--
Propranolol HydrochlorideTablet40mgSDL--
Propranolol HydrochlorideTablet80mgSDL--
Propylene Glycol In Aqueous CreamCream20%SDL--
Propylene Glycol In Aqueous CreamCream40%SDL--
PropylthiouracilTablet50mgSDL--
Protamine SulfateInjection1% (10mg/ mL)SDL--
PyrazinamideTablet500mgSDL--
Pyridostigmine BromideTablet10mgSDL--
Pyridostigmine BromideTablet60mgSDL--
Pyridoxine HydrochlorideTablet10mgSDL--
Pyridoxine HydrochlorideTablet50mgSDL--
PyrimethamineTablet25mgSDL--
Active Ingredient(s) Dosage Form Strength Subsidy Class Clinical Indication (where applicable)
QuetiapineTablet25mgSDL--
QuetiapineTablet100mgSDL--
QuetiapineTablet200mgSDL--
Quinidine SulfateTablet200mgSDL--
Quinine SulfateTablet300mgSDL--
Active Ingredient(s) Dosage Form Strength Subsidy Class Clinical Indication (where applicable)
Rabies Virus Vaccine (Inactivated)Injectionminimum 2.5 international unitSDL--
RifampicinCapsule150mgSDL--
RifampicinCapsule300mgSDL--
Risedronate SodiumTablet5mgMAF1) For patients with osteoporosis (T-score <= -2.5)
2) For patients with osteopenia (T-score <= -1.5) and a history of non-trauma induced fracture
Risedronate SodiumTablet35mgMAF1)  For patients with osteoporosis (T-score <= -2.5)
2) For patients with osteopenia (T-score <= -1.5) and a history of non-trauma induced fracture
RisperidoneOral Solution1mg/ mLSDL--
RisperidoneTablet0.5mgSDL--
RisperidoneTablet1mgSDL--
RisperidoneTablet2mgSDL--
RituximabConcentrate for Infusion100mg/ 10mLMAF1) Treatment of patients with CD20 positive diffuse large B cell lymphoma
2) Treatment of patients with CD20 positive follicular non-Hodgkin's lymphoma
RituximabConcentrate for Infusion500mg/ 50mLMAF1) Treatment of patients with CD20 positive diffuse large B cell lymphoma
2) Treatment of patients with CD20 positive follicular non-Hodgkin's lymphoma
RivaroxabanTablet15mgMAF1) Prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation (NVAF), and
  • CHA2DS2-VASc score of 1 or more for men, and
  • CHA2DS2-VASc score of 2 or more for women.
Rivaroxaban should not be used in people with valvular AF (especially rheumatic mitral stenosis), or people with prosthetic heart valves.
2) Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE in adults. MAF assistance does not apply to patients with isolated distal DVT.
RivaroxabanTablet20mgMAF1) Prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation (NVAF), and
  • CHA2DS2-VASc score of 1 or more for men, and
  • CHA2DS2-VASc score of 2 or more for women.
Rivaroxaban should not be used in people with valvular AF (especially rheumatic mitral stenosis), or people with prosthetic heart valves.
2) Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE in adults. MAF assistance does not apply to patients with isolated distal DVT.
RivastigmineTransdermal Patch4.6mg/24hrMAFChecklist to be completed
1) Rivastigmine patch formulation (4.6mg/24hr and 9.5mg/24hr) for the treatment of moderately severe dementia associated with Parkinson's disease in patients who have behavioural symptoms.
2) Rivastigmine patch formulation (4.6mg/24hr, 9.5mg/24hr and 13.3mg/24hr) for the treatment of moderately severe dementia associated with Alzheimer's disease in patients who have behavioural symptoms.
RivastigmineTransdermal Patch9.5mg/24hrMAFChecklist to be completed
1) Rivastigmine patch formulation (4.6mg/24hr and 9.5mg/24hr) for the treatment of moderately severe dementia associated with Parkinson's disease in patients who have behavioural symptoms.
2) Rivastigmine patch formulation (4.6mg/24hr, 9.5mg/24hr and 13.3mg/24hr) for the treatment of moderately severe dementia associated with Alzheimer's disease in patients who have behavioural symptoms.
RivastigmineTransdermal Patch13.3mg/24hrMAFChecklist to be completed
1) Rivastigmine patch formulation (4.6mg/24hr, 9.5mg/24hr and 13.3mg/24hr) for the treatment of moderately severe dementia associated with Alzheimer's disease in patients who have behavioural symptoms.
RopiniroleTablet0.25mgSDL--
RopiniroleTablet1mgSDL--
RopiniroleTablet2mgSDL--
Rose BengalSingle-Use Eye Drops 1% (preservative free)SDL--
Rubella Virus Vaccine (live-attenuated)Injectionminimum 1,000 TCID 50/ 0.5mLSDL--
Active Ingredient(s) Dosage Form Strength Subsidy Class Clinical Indication (where applicable)
SalbutamolInhaler100mcg/ doseSDL--
SalbutamolNebulisation Solution0.50%SDL--
SalbutamolConcentrate for Infusion5mg/ 5mLSDL--
SalbutamolOral Liquid2mg/ 5mLSDL--
SalbutamolTablet2mgSDL--
Salicylic AcidCream2%SDL--
Salicylic AcidCream20%SDL--
Salicylic AcidOintment2%SDL--
Salicylic AcidOintment5%SDL--
Salicylic AcidOintment10%SDL--
Salicylic AcidOintment40%SDL--
Salicylic Acid & Lactic AcidTopical SolutionSalicylic Acid 16.7% + Lactic Acid 16.7% CollodionSDL--
Salicylic Acid & Lactic AcidTopical SolutionSalicylic Acid 17% + Lactic Acid 17% CollodionSDL--
Salmeterol & Fluticasone PropionateInhalerSalmeterol 25mcg/ dose + Fluticasone Propionate 50mcg/ doseSDL--
Salmeterol & Fluticasone PropionateInhalerSalmeterol 25mcg/ dose + Fluticasone Propionate 125mcg/ doseSDL--
Salmeterol & Fluticasone PropionateInhalerSalmeterol 25mcg/ dose + Fluticasone Propionate 250mcg/ doseSDL--
Salmeterol & Fluticasone PropionatePowder InhalerSalmeterol 50mcg/ dose + Fluticasone Propionate 100mcg/ doseSDL--
Salmeterol & Fluticasone PropionatePowder InhalerSalmeterol 50mcg/ dose + Fluticasone Propionate 250mcg/ doseSDL--
Salmeterol & Fluticasone PropionatePowder InhalerSalmeterol 50mcg/ dose + Fluticasone Propionate 500mcg/ doseSDL--
Sea Snake Venom AntiserumConcentrate for Infusion1,000 unit/ doseSDL--
Selenium SulfideTopical Suspension2.50%SDL--
SennosidesTablet7.5mgSDL--
SertralineTablet50mgSDL--
Silicone CreamCreamDimethicone 10% + Chlorocresol 0.1%SDL--
SimeticoneOral Suspension100mg/ mLSDL--
SimvastatinTablet10mgSDL--
SimvastatinTablet20mgSDL--
SirolimusTablet0.5mgMAFFor kidney transplant immunosuppression in patients with:
1) Evidence of CNI-induced nephrotoxicity on allograft biopsy OR
2) Elevated serum creatinine levels precluding the achievement of optimal therapeutic blood levels of CNI OR
3) History of CNI drug hypersensitivity
SirolimusTablet1mgMAFFor kidney transplant immunosuppression in patients with:
1) Evidence of CNI-induced nephrotoxicity on allograft biopsy OR
2) Elevated serum creatinine levels precluding the achievement of optimal therapeutic blood levels of CNI OR
3) History of CNI drug hypersensitivity
SirolimusTablet2mgMAFFor kidney transplant immunosuppression in patients with:
1) Evidence of CNI-induced nephrotoxicity on allograft biopsy OR
2) Elevated serum creatinine levels precluding the achievement of optimal therapeutic blood levels of CNI OR
3) History of CNI drug hypersensitivity
SirolimusOral Solution1mg/ mLMAFFor kidney transplant immunosuppression in patients with:
1) Evidence of CNI-induced nephrotoxicity on allograft biopsy OR
2) Elevated serum creatinine levels precluding the achievement of optimal therapeutic blood levels of CNI OR
3) History of CNI drug hypersensitivity
Sodium Alginate, Sodium Bicarbonate & Calcium CarbonateOral SuspensionSodium Alginate 500mg/ 10mL + Sodium Bicarbonate 267mg/ 10mL + Calcium Carbonate 160mg/ 10mLSDL--
Sodium BicarbonateInfusion4.20%SDL--
Sodium BicarbonateInfusion8.40%SDL--
Sodium BicarbonateInjection4.20%SDL--
Sodium BicarbonateInjection8.40%SDL--
Sodium BicarbonateCapsule500mgSDL--
Sodium BicarbonatePowderMinimum 99%SDL--
Sodium Bicarbonate & Sodium ChloridePowder9 parts Sodium Bicarbonate + 1 part Sodium ChlorideSDL--
Sodium Calcium EdetateInjection200mg/ mLSDL--
Sodium ChlorideInfusion0.45%SDL--
Sodium ChlorideInfusion0.90%SDL--
Sodium ChlorideInfusion3%SDL--
Sodium ChlorideInfusion20%SDL--
Sodium ChlorideInjection0.45%SDL--
Sodium ChlorideInjection0.90%SDL--
Sodium ChlorideInjection3%SDL--
Sodium ChlorideInjection20%SDL--
Sodium ChlorideEye Drops0.90%SDL--
Sodium ChlorideEye Drops5%SDL--
Sodium ChlorideEye Ointment5%SDL--
Sodium Chloride, Calcium Chloride Dihydrate & Potassium ChlorideInfusionSodium Chloride 8.6g/ L + Calcium Chloride Dihydrate 0.33g/ L + Potassium Chloride 0.3 g/ LSDL--
Sodium Laurylsulfoacetate & Sodium CitrateEnemaSodium Laurylsulfoacetate 9mg/ mL + Sodium Citrate 90mg/ mL + Sorbitol 625mg/ mLSDL--
Sodium NitriteInjection3%SDL--
Sodium NitroprussideInjection10mg/ mLSDL--
Sodium Polystyrene SulfonateOral Suspension15g/ 60mLSDL--
Sodium Polystyrene SulfonatePowder for Oral Suspension99%SDL--
Sodium Tetradecyl SulfateInjection1%SDL--
Sodium Tetradecyl SulfateInjection3%SDL--
Sodium ThiosulfateInjection25%SDL--
Sodium ThiosulfateOral Solution25%SDL--
Sodium ThiosulfatePowder50gSDL--
Sodium ValproateControlled-Release Tablet200mgSDL--
Sodium ValproateControlled-Release Tablet300mgSDL--
Sodium ValproateControlled-Release Tablet500mgSDL--
Sodium ValproateEnteric-Coated Tablet200mg SDL--
Sodium ValproateInjection400mgSDL--
Sodium ValproateSyrup200mg/ 5mL SDL--
Somatostatin (as Acetate)Infusion3mgSDL--
SomatropinPrefilled Pen10mg/ 1.5 mLMAFTreatment of children with short stature due to conditions associated with growth failure.
  • Somatropin is not recommended for the treatment of idiopathic short stature.
SomatropinInjection4mg MAFTreatment of children with short stature due to conditions associated with growth failure.
  • Somatropin is not recommended for the treatment of idiopathic short stature.
SomatropinPrefilled Pen5mg/ 1.5 mLMAFTreatment of children with short stature due to conditions associated with growth failure.
  • Somatropin is not recommended for the treatment of idiopathic short stature.
SomatropinInjection6mg MAFTreatment of children with short stature due to conditions associated with growth failure.
  • Somatropin is not recommended for the treatment of idiopathic short stature.
Somatropin Injection3.33mg MAFTreatment of children with short stature due to conditions associated with growth failure.
  • Somatropin is not recommended for the treatment of idiopathic short stature.
SpironolactoneTablet25mgSDL--
StreptokinaseInfusion1.5 million international unit SDL--
StreptomycinInjection1gSDL--
StreptomycinInjection5gSDL--
Sulfadiazine SilverCream1%SDL--
Sulfamethoxazole & TrimethoprimConcentrate for InfusionSulfamethoxazole 80mg/ mL + Trimethoprim 16mg/ mLSDL--
Sulfamethoxazole & TrimethoprimSuspensionTrimethoprim 40mg/ 5mL + Sulphamethoxazole 200mg/ 5mLSDL--
Sulfamethoxazole & TrimethoprimTabletTrimethoprim 20mg + Sulphamethoxazole 100mgSDL--
Sulfamethoxazole & TrimethoprimTabletTrimethoprim 80mg + Sulphamethoxazole 400mgSDL--
SulfasalazineEnteric-Coated Tablet500mgSDL--
Sulphur & Salicylic AcidCreamSulphur 4% + Salicylic Acid 2%SDL--
Sulphur, Resorcinol & CalamineLotionSulphur 4% + Resorcinol 2% + Calamine 10%SDL--
SulpirideTablet200 mgSDL--
SumatriptanTablet50mgSDL--
Suxamethonium ChlorideInjection50mg/ mLSDL--
Active Ingredient(s) Dosage Form Strength Subsidy Class Clinical Indication (where applicable)
TacrolimusOintment0.03%MAF1) Treatment of moderate to severe atopic dermatitis in adults and adolescents (16 years of age and above) who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids
2) Treatment of moderate to severe atopic dermatitis in children (2 years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids
TacrolimusOintment0.10%MAFTreatment of moderate to severe atopic dermatitis in adults and adolescents (16 years of age and above) who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids
TacrolimusProlonged-Release Capsule0.5mgSDL--
TacrolimusProlonged-Release Capsule1mgSDL--
TacrolimusProlonged-Release Capsule5mgSDL--
TacrolimusCapsule0.5mgSDL--
TacrolimusCapsule1mgSDL--
TacrolimusCapsule5mgSDL--
TamoxifenTablet10mgSDL--
TamoxifenTablet20mgSDL--
Temozolomide (generic)Capsule20mgSDL--
Temozolomide (generic)Capsule100mgSDL--
Tenofovir Disoproxil FumarateTablet 300mgMAFTreatment of patients with chronic hepatitis B infection for whom nucleos(t)ide analogue therapy is indicated, whether treatment-naïve or experienced
TerazosinTablet2mgSDL--
TerazosinTablet5mgSDL--
Testosterone CipionateInjection100mg/ mLSDL--
Tetanus Immunoglobulin (Human)Injection250 unit/ doseSDL--
Tetanus Toxoid VaccineInjectionminimum 40 international unit/ 0.5mLSDL--
Tetracycline HydrochlorideOintment3%SDL--
Tetracycline HydrochlorideCapsule250mgSDL--
TheophyllineSustained-Release Tablet125mgSDL--
TheophyllineSustained-Release Tablet200mgSDL--
TheophyllineSustained-Release Tablet250mgSDL--
TheophyllineSustained-Release Tablet300mgSDL--
TheophyllineSyrup80mg/ 15mLSDL--
TheophyllineTablet125mgSDL--
Thiamine HydrochlorideInjection100mg/ mLSDL--
Thiamine HydrochlorideTablet10mgSDL--
Thiopental SodiumInjection0.5gSDL--
Thiopental SodiumInjection1gSDL--
ThrombinTopical Solution5,000 international unit/ 5mLSDL--
Ticlopidine HydrochlorideTablet250mgSDL--
Timolol MaleateEye Drops0.25%SDL--
Timolol MaleateEye Drops0.50%SDL--
TioguanineTablet40mgSDL--
TolbutamideTablet500mgSDL--
Tolterodine TartrateExtended-Release Capsule4mgSDL--
Tolterodine TartrateTablet1mgSDL--
Tolterodine TartrateTablet2mgSDL--
TopiramateTablet25mgSDL--
TopiramateTablet50mgSDL--
TopiramateTablet100mgSDL--
Tramadol HydrochlorideCapsule50mgSDL--
Tramadol HydrochlorideTablet50mgSDL--
Tranexamic AcidInjection 100mg/ mLSDL--
Tranexamic AcidTablet500mgSDL--
TrastuzumabInfusion440mgMAF1) Treatment of women with HER2-positive early breast cancer who are axillary lymph node positive
2) Treatment of women with HER2-positive early breast cancer with tumour size greater than 1cm and are axillary lymph node negative
3) Treatment of HER2-positive metastatic breast cancer, in the following circumstances:
  • in combination with a taxane for patients who have not received chemotherapy for their metastatic disease,
  • or
  • in combination with an aromatase inhibitor for postmenopausal patients with hormone-receptor positive metastatic breast cancer, not previously treated with trastuzumab.
TretinoinCapsule10mgSDL--
Triamcinolone AcetonideInjection10mg/ mLSDL--
Triamcinolone AcetonideNasal Spray55mcg/ doseSDL--
Triamterene & HydrochlorothiazideTabletTriamterene 50mg + Hydrochlorothiazide 25mgSDL--
TrifluoperazineTablet1mgSDL--
TrifluoperazineTablet5mgSDL--
TrimethoprimOral Suspension50mg/ 5mLSDL--
TrimethoprimTablet100mgSDL--
TropicamideEye Drops0.50%SDL--
TropicamideEye Drops1%SDL--
TropicamideSingle-Use Eye Drops1%SDL--
Typhoid Vaccine (salmonella typhi Vi polysaccharide Ty2 strain) (Killed vaccine)Injection25mcg/ 0.5mLSDL--
Active Ingredient(s) Dosage Form Strength Subsidy Class Clinical Indication (where applicable)
UreaCream5%SDL--
UreaCream10%SDL--
Active Ingredient(s) Dosage Form Strength Subsidy Class Clinical Indication (where applicable)
ValganciclovirTablet450mgSDLPrevention of cytomegalovirus infection after solid organ transplant
ValsartanTablet80mgSDL--
ValsartanTablet160mgSDL--
VancomycinInfusion500mgSDL--
VasopressinInjection20 pressor unit/ mLSDL--
VenlafaxineExtended-Release Capsule75mgSDL--
VenlafaxineExtended-Release Capsule150mgSDL--
Verapamil HydrochlorideInjection2.5mg/ mLSDL--
Verapamil HydrochlorideTablet40mgSDL--
Vinblastine SulfateInjection10mgSDL--
Vincristine SulfateInjection1mgSDL--
Vitamin ACapsule10,000 unitSDL--
Vitamin B ComplexInjectionThiamine Hydrochloride 10mg/ 2mL + Sodium Riboflavin Phosphate 4mg/ 2mL + Nicotinic Acid 40mg/ 2mL + Panthenol 6mg/ 2mL + Biotin 5mg/ 2mL + Pyridoxine Hydrochloride 4mg/ 2mL + Cyanocobalamin 8mcg/ 2mLSDL--
Vitamin B ComplexTabletThiamine 3mg + Riboflavine 1.5mg + Nicotinamide 10mg + Pyridoxine 0.5mgSDL--
VoriconazoleOral Suspension40mg/ mlMAF1) Treatment of invasive aspergillosis
2) Treatment of candidemia in non-neutropenic patients
3) Treatment of fluconazole-resistant candidiasis
4) Treatment of serious infections from Scedosporium and Fusarium species.
VoriconazoleTablet50mg, 200mgMAF1) Treatment of invasive aspergillosis
2) Treatment of candidemia in non-neutropenic patients
3) Treatment of fluconazole-resistant candidiasis
4) Treatment of serious infections from Scedosporium and Fusarium species.
Voriconazole Infusion200mgMAF1) Treatment of invasive aspergillosis
2) Treatment of candidemia in non-neutropenic patients
3) Treatment of fluconazole-resistant candidiasis
4) Treatment of serious infections from Scedosporium and Fusarium species.
Active Ingredient(s) Dosage Form Strength Subsidy Class Clinical Indication (where applicable)
Warfarin SodiumTablet1mgSDL--
Warfarin SodiumTablet3mgSDL--
Warfarin SodiumTablet5mgSDL--
White Soft ParaffinOintment--SDL--
Active Ingredient(s) Dosage Form Strength Subsidy Class Clinical Indication (where applicable)
Yellow Fever Virus Vaccine (live-attenuated)Injectionminimum 1,000 LD50 unitSDL--
Active Ingredient(s) Dosage Form Strength Subsidy Class Clinical Indication (where applicable)
Zoledronic AcidInfusion5mg/ 100mLMAF1) For patients with osteoporosis (T score <= -2.5) and who are unable to tolerate or follow the administration instructions for oral bisphosphonates
2) For patients with FRAX of >= 20 for major osteoporotic fractures and >= 3 for hip fractures and who are unable to tolerate or follow the administration instructions for oral bisphosphonates
Zoledronic AcidInfusion4mgMAF1) Treatment of metastatic bone lesions from solid tumours and multiple myeloma.
2) Treatment of hypercalcaemia of malignancy.
Zuclopenthixol AcetateInjection50mg/ mLSDL--
Zuclopenthixol DecanoateInjection200mg/ mLSDL--